Jaguar Health Inc (NASDAQ: JAGX) stock jumped 11.37% on Friday to $0.41 against a previous-day closing price of $0.37. With 3.84 million shares changed hands, the volume of the stock remained lighter than its average volume of 4.35 million shares. The 52-week range on JAGX shows that it touched its highest point at $11.40 and its lowest point at $0.21 during that stretch. It currently has a 1-year price target of $6.00. Beta for the stock currently stands at 1.72.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of JAGX was up-trending over the past week, with a rise of 39.21%, but this was up by 15.48% over a month. Three-month performance dropped to -13.69% while six-month performance fell -38.73%. The stock lost -96.01% in the past year, while it has lost -93.76% so far this year. EPS is expected to grow by 40.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 80.25%.
Float and Shares Shorts:
At present, 19.12 million JAGX shares are outstanding with a float of 13.69 million shares on hand for trading. On Oct 30, 2023, short shares totaled 1.12 million, which was 5.88% higher than short shares on Sep 28, 2023. In addition to Ms. Lisa A. Conte as the firm’s Founder, CEO, President & Director, Dr. Pravin R. Chaturvedi Ph.D. serves as its Chief Scientific Officer & Chair of Scientific Advisory Board.
Institutional Ownership:
Through their ownership of 2.05% of JAGX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.33% of JAGX, in contrast to 1.69% held by mutual funds. Shares owned by individuals account for 1.49%. As the largest shareholder in JAGX with 1.01% of the stake, The Vanguard Group, Inc. holds 192,335 shares worth 192,335. A second-largest stockholder of JAGX, Geode Capital Management LLC, holds 92,333 shares, controlling over 0.48% of the firm’s shares. JPMorgan Securities LLC is the third largest shareholder in JAGX, holding 85,384 shares or 0.45% stake. With a 1.01% stake in JAGX, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 192,335 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.47% of JAGX stock, is the second-largest Mutual Fund holder. It holds 89,781 shares valued at 31064.0. Fidelity Series Total Market Inde holds 0.01% of the stake in JAGX, owning 891 shares worth 308.0.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for JAGX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With JAGX analysts setting a high price target of $6.00 and a low target of $6.00, the average target price over the next 12 months is $6.00. Based on these targets, JAGX could surge 1363.41% to reach the target high and rise by 1363.41% to reach the target low. Reaching the average price target will result in a growth of 1363.41% from current levels.
Summary of Insider Activity:
Insiders traded JAGX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 25 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 1,380,182 while 0 shares were sold.
